Compare Amylx Pharmaceuticals Inc (AMLX) vs Suncor Energy Inc. (SU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Suncor Energy Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Suncor Energy Inc. trades at $59.85 (market cap $69.71B). The key difference: Suncor Energy Inc. is far larger — about 35.2× Amylx Pharmaceuticals Inc's market cap, and Suncor Energy Inc. pays a 2.85% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SU | |
|---|---|---|
Market Cap | $1.98B | $69.71B |
Sector | Health | Energy |
52-Week High | $18.70 | $69.73 |
52-Week Low | $7.64 | $38.17 |
Enterprise Value | $1.70B | $77.84B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Suncor Energy (SU) trades at $59.25, up 1.3% today, with strong analyst support (74% buy ratings) and bullish technical signals. The stock shows solid fundamentals with a P/E of 15.99, net margin of 11.62%, and consistent dividend payments. Recent Q1 2026 earnings missed expectations, but Q3 and Q4 2025 results exceeded forecasts. Cash flow remains positive with $166M net inflow in 2025.
Outlook remains positive with expected revenue growth to $54.5B in 2026 and improving profit margins. Key risks include oil price volatility and operational challenges. The stock presents value opportunity with attractive valuation metrics and strong institutional support, though investors should monitor Q2 2026 earnings results against the $2.26 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
